About Us

Ann holds a Ph.D. in Science from the University of Antwerp (Biology/Pharmacology) and a Master in Management from The University of Antwerp and Middle Management MBA from Vlerick Business School.

Ann has extensive experience (30+ years) in drug development. In her previous role as a compound development team leader in a big pharma company, she brought several products from discovery to the early clinical proof of concept phase and subsequently led and managed the early development portfolio of a spinout company. Amongst others, Ann has guided a clinical-stage biotech as Chief Development Officer, while supporting several companies in evaluating, selecting, and developing products, often in interim management roles (CSO/CEO).

Ronald is a Board-certified MD, Anesthesiologist. He completed an ACGME-accredited Pediatric Anesthesia fellowship at Boston Children’s Hospital and holds the European Diploma in Intensive Care Medicine.

He worked for many years as a senior staff physician in the Pediatric Intensive Care Unit at Leiden University Medical Center and built a research program centered on the generation and structural characteristics of differentiated cells containing microtubuli, dyneins and centriolar proteins.

Tomas has more than 30 years of experience in financial management in both big multinationals and small, local companies covering a broad range of industries. After starting his career at Procter & Gamble, he turned to the pharma industry by joining Johnson & Johnson, where he held various financial roles in production and commercial organizations.  Banking on that experience he became Finance Director at Movetis, a spin-off from Janssen Pharmaceutica. After that, Tomas held Finance Director and CFO roles in various Belgian companies with a focus on business partnership, process excellence, and strategic finance.

Currently, Tomas is CFO at 2 Bridge, AbolerIS Pharma, and DeuterOncology.

Pascal has around 25 years of experience in leading drug discovery and preclinical development programs and teams at several biotech companies.

At the start of his career, he has been working with technology platforms around functional genomics at Galapagos and gene therapy at Introgene. During his time at Ablynx, Thombogenics, Tusk Therapeutics and Oncurious he obtained extensive experience with developing biologicals by accelerating programs towards the clinic across different therapeutic areas. Pascal earned his PhD in Biomedical Sciences from KU Leuven.

Carole holds a PhD in Immunology from University of Paris VII. Currently, Carole is Director of Research 1st class at the CNRS, team 2 leader at the CR2TI and director of the FOCIS Center of Excellence Nantes University. Carole is co-founder and Head of Research of AbolerIS Pharma.

After a PhD, Carole joined the laboratory of Pr Doherty, Nobel Prize winner in medicine, in Australia, thanks to a European Marie Curie scholarship. In 2009, she was recruited by the CNRS and joined the CR2TI in Nantes. Carole is interested in understanding the mechanisms of tolerance through the study of regulatory T cells. Member of several learned scientific societies, Carole coordinates projects leading to the discovery of several therapeutic targets involved in the pathological responses of autoimmune diseases. Carole is the inventor of 19 patents. Carole was rewarded several prizes including from the National Academy of Medicine and the Fondation de France.

Benoit has more than 25 years of experience in a variety of positions within pharmaceutical development with responsibilities in the field of research and development (3 NMEs in phase I),  quality assurance, regulatory affairs and manufacturing, as well as nearly 10 years of experience in different C-level roles, such as CSO, CTO & COO.

Experience in young biotech companies to develop the strategic development plan for new medicinal products, meetings with investors, and authorities (EMA, FDA, AFMPS), managing CROs and CMOs

Antoine is a CMC expert bringing more than 20 year’s experience acquired in the pharmaceutical industry in the development, manufacturing, clinical supply and regulatory review (FDA, EMA) of several new drugs entities.

Antoine managed various programs for small to middle-size Biotech in the fields of small molecules (NCEs), Biologicals (NBEs) and gene therapy (ATMPs), leading pre-clinical drug candidates to first-in-human studies (3 INDS/IMPDs for phase 1), through late stage (1 IND/IMPD for phase 3) and up to commercial launch (1 BLA/MAA for Cablivi®). Antoine holds a PhD in Organic Chemistry from the Université Henri Poincaré Nancy 1 (FR)

Dr. Frédéric Legros is an established biotech leader with more than 15 years of Corporate and business development experience in the biotechnology industry. Currently CEO and Chairman of ARTHEx Biotech. Between January 2017 and October 2022, he served as Chief Operating Officer of Dynacure, a company he co-founded. Prior to launching Dynacure, and until December 2016, Dr. Legros served as Vice President and Corporate Head of Business Development of Valneva SE, a biotech company listed on the French stock exchange.
Dr. Legros studied biotechnology and received his Ph.D. in molecular biology from the University of Paris 7. He also holds a business degree from NEOMA Business School, France.

Ann holds a Ph.D. in Science from the University of Antwerp (Biology/Pharmacology) and a Master in Management from The University of Antwerp and Middle Management MBA from Vlerick Business School.

Ann has extensive experience (30+ years) in drug development. In her previous role as a compound development team leader in a big pharma company, she brought several products from discovery to the early clinical proof of concept phase and subsequently led and managed the early development portfolio of a spinout company. Amongst others, Ann has guided a clinical-stage biotech as Chief Development Officer, while supporting several companies in evaluating, selecting, and developing products, often in interim management roles (CSO/CEO).

Guy holds an M.D., Internal Medicine, degree from the University of Liège, and is currently a partner in Newton Biocapital, acting as CMO and Regulatory Officer. Guy practiced medicine for 12 years before joining the pharmaceutical industry.

Guy has extensive experience (30+ years) in the Pharmaceutical Industry (Pfizer) as an International Medical Director and European Team leader for neurodegenerative diseases. Guy has developed experience and skills in clinical development for drugs in immunology, rheumatology, bone, metabolic diseases, infectious diseases, and Alzheimer’s disease areas. Guy has also contributed to the successful market introduction of multiple products.

Pablo graduated in Chemistry from the University of Buenos Aires, and holds a Ph.D. in Organic Chemistry from the University of Barcelona. From 2005 to 2009, he was a postdoctoral Fulbright Fellow at the Department of Systems Biology at Harvard University. Pablo joined Criteria Bio Venture in 2018, holding the Director of the Life Science Investment Funds position. Criteria Bio Venture is the specialized Fund in the Life Science sector within Caixa Capital Risc, the venture capital arm of Criteria Caixa.

Pablo has extensive experience in early-stage investment, supporting the spinning out of several academic technologies when he was the Director of the Technology and Business Development Office at the Center for Genomics Regulation.  Moreover, he has an extensive career as an investor and also as a Board member in preclinical and clinical-stage companies. He has been on the Board of Directors of several Biotech companies such as SpliceBio, iProteos, Aptatarget, Glycardial, and Sanifit (recently acquired by Vifor Pharma), and he currently serves on the Board of Directors at Medlumics, Aelix Therapeutics and Minoryx Therapeutics.

Bibhash is a venture capital fund manager, investor, company builder and board member with around decade and half of experience in biotech. Prior to founding Sound Bioventures, Bibhash worked as an investor with a therapeutic area focused fund (Pivotal) and with the biotech practice of a large, diversified venture fund (NEA). Prior to that he has operating experience in BD and corporate strategy from both AstraZeneca and Johnson & Johnson.

He has been involved in numerous private investments, M&A deals and IPOs from venture experience and multiple major in-licensing, divestiture and acquisitions from pharma experience, in multiple cross-border (Europe / US) deals and on boards of multiple private and public companies as well as advisory roles in incubators. His education spans 3 continents culminating with a PhD in the biology of retinal degeneration from Baylor College of Medicine.

Caroline THIELEN currently holds the position of Investment Manager – Life Sciences at WE (Wallonie Entreprendre) and serves as Board Member for multiple biotech and medtech companies. Prior to joining WE, she dedicated over 20 years to coordinating research projects at both national and international levels. Notably, she assumed the role of Chief Operating Officer at Bridge2Health (B2H), an organization focused on advancing and strengthening the healthcare sector in Liège.

Caroline’s academic accomplishments include a Master’s degree in Biology and a PhD in Immunology form the University of Liège, further enriched by completing postdoctoral training at the Centers for Disease Control and Prevention (CDC) in Atlanta, USA.

Alain has 20 years international experience in food and biotech industry as well as 20 years in venture capital. He has been a lead investor for many investments in early and neglected late-stage companies that he then brought through to an IPO or M&A transaction, including Ogeda (sold to Astellas for EUR 800 million).

Ruben is an Associate at Criteria Bio Ventures investing in and building biotech companies. He currently serves as a Board Observer of AbolerIS Pharma. Before joining Criteria Bio Ventures, Ruben was a Technology and Business Development fellow at the Centre for Genomic Regulation (CRG) technology transfer office, where he advised entrepreneurs on R&D, intellectual property protection, and commercialization strategies. He has also provided due diligence support as an independent consultant to early-stage investment firms in Spain and the US.

Ruben holds a Ph.D. in Biomedicine from the Centre for Genomic Regulation (CRG), where he studied genome organization and epigenetics in stem cells and during cellular reprogramming and contributed to developing novel cell therapies for regenerative medicine, and a master’s degree in Cancer Biology from the University of Barcelona.

Thomas is a Principal at Sound Bioventures. Prior to that, he was a Snr. Principal at Lundbeckfonden Ventures. Thomas has also advised biotech and pharma in a strategy consultant capacity. Before that, Thomas started his own company in Cambridge, UK. Thomas received his postdoctoral training at the University of Cambridge, UK after earning his D. Phil. in Medical Sciences from the University of Oxford, UK, and his MSc in Biochemistry from the University of Copenhagen, DK.

Thomas currently also serves as a board observer at Breye, VarmX, and Teitur Trophics.

Since 2020, Camille has joined Turenne Capital as an associate in the healthcare Team. She is working in the Venture Capital team that manages the funds Relyens Innovation Santé an evergreen vehicle specializing in health innovation controlled and owned by Relyens, a mutual insurance company specializing in the risk management of health, social, and medical players. Relyens Innovation Santé’s mission is to support the growth and development phases of innovative companies in the health sector.

Camille worked as a financial analyst in M&A/Licensing & Acquisition at Pierre Fabre Laboratories (Paris). Camille then joined Sanofi in Boston (USA) as a Clinical Trial Finance Manager where she oversaw the construction and monitoring of clinical study budgets. Just before joining Turenne, she oversaw business development and strategic marketing at Adocia, a biotechnology company listed on Euronext.